-
Risk managers often look at the emergency department as a little like a container of potato salad left out in the sun. Its a Petri dish for all the terrible things that can happen in your hospital, says one expert. That attitude has some basis in fact, she says, but there are specific actions you can take to reduce the risk.
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA).
-
Palonosetron, developed by MGI Pharma and its partner Helsinn Healthcare SA, is a recently approved selective antagonist of serotonin subtype 3 receptors (5-HT3).
-
The following drugs are in various stages of clinical studies and trials.
-
By calling an 800 number and paying a $5 fee, residents in four Wyoming cities can have face-to-face consultations with clinical pharmacists, who not only review the residents health and medication history but make cost-saving suggestions as well.
-
All AEs will be assessed by the investigator using the protocol-defined grading system. If the protocol has no defined grading system, or if the AE is not described in the existing grading system, the following guidelines should be used to qualify severity.
-
No investigator or coordinator wants to believe it could happen. But in clinical trials, injuries or adverse events are always a possibility. The question for many is, What will happen to study subjects who are injured in the course of their research participation?
-
The recent lawsuit against Abiomed Inc. of Danvers, MA, and others involved in clinical trials involving the AbioCor Implantable Replacement Heart shows that sometimes the best preparation and informed consent process still cannot prevent litigation.
-
Director Argues for Rigorous CAM Research; WHO Issues Guidelines About Medicinal Plant Production and Collection; One-third of CAM Centers Have No Physician Involvement. Altern Ther Women's Health 2004;6(3):23-24.
-
O'Mathuna DP. Therapeutic touch for pain. Altern Ther Women's Health 2004;6(3):17-20.
